NCT04354545RecruitingAccepts Healthy Volunteers

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

University of California, Los Angeles

Start Date

4/1/2021

Completion Date

12/1/2026

Summary

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Detailed Description

To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma antihypertensive medications.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: * Currently using one or more topical glaucoma antihypertensives * Self-described symptoms of ocular surface discomfort * Xiidra is being prescribed as part of the subject's standard care Exclusion Criteria: * History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.), * current use of topical cyclosporine * current use of topical steroids * incisional ocular surgery within 6 months

Interventions

DRUG

Xiidra (Lifitegrast ophthalmic solution) 5%

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

GlaucomaOcular Surface Disease

Locations

Doheny Eye Center UCLA

Fountain Valley, California 92708

United States